|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of US Patent RE43916
What is the Scope of US Patent RE43916?
US Patent RE43916 pertains to methods of producing or improving a specific class of drugs, potentially related to pharmaceuticals in the treatment of particular conditions. As a reissue patent, its scope is intended to clarify or correct the original patent's claims but generally remains centered on specific drug formulations, synthesis processes, or therapeutic applications.
- Reissue status indicates that the patent was reexamined after issuance, often to correct errors or adjust claims.
- The patent covers a method of manufacturing or a formulation involving a specific compound or combination.
- The claims focus on the novel aspects of the synthesis process, pharmaceutical composition, or therapeutic indications.
The domain of the patent likely intersects with drug candidates or delivery methods related to the patent owner’s portfolio in the therapeutic area. If the patent references a particular drug compound or method, the detailed description specifies the chemical entities, pharmaceutical forms, or administration routes protected.
What are the Key Claims?
The claims in RE43916 define the boundaries of patent protection. Typically, these would include:
- Process claims detailing specific steps of a chemical or pharmaceutical synthesis, including reagents, conditions, and intermediates.
- Composition claims covering the final drug formulations, excipients, or delivery systems.
- Use claims describing therapeutic methods or indications enabled by the invention.
Example Claim Breakdown
| Type of Claim |
Scope |
Specificity |
| Process Claim |
Methods of synthesizing a particular compound under defined conditions |
May specify temperature, catalysts, solvents |
| Composition Claim |
A pharmaceutical formulation comprising a specific active ingredient and excipient |
Focuses on ratios, forms (tablet, injection) |
| Use Claim |
Treatment of a disease using the specified compound or formulation |
Defines therapeutic indications (e.g., depression, cancer) |
The claims are likely to be narrow relative to broader patents, often emphasizing a particular synthesis pathway or formulation.
Patent Landscape and Related Patents
The patina surrounding RE43916 involves:
Prior Art and Related Patents
- Similar patents exist, covering chemical compounds, drug delivery methods, or treatment indications.
- Patent families in the same therapeutic area include filings in the U.S., Europe, and Asia, often showing a layered strategy of composition, process, and use claims.
- The patent's priority date (unknown here, but typically several years before reissue) influences its standing against prior art.
CompetitorPatents and Freedom to Operate
- Competing firms hold patents on related compounds or synthesis techniques, creating a complex landscape of overlapping claims.
- Freedom-to-operate analyses indicate that the patent may block certain approaches to manufacturing or using the drug, especially if the claims are narrow but enforceable.
- Court battles or patent office challenges (examinations, reexaminations) could influence the enforceability or scope of RE43916.
Patent Term and Maintenance
- As a reissue patent, RE43916 may have a shortened or extended term, subject to adjustments or extensions based on regulatory delays.
- Maintenance fees typically due at 3.5, 7.5, and 11.5 years from grant, ensuring ongoing enforceability.
Legal Status and Enforcement
- The patent remains enforceable unless challenged successfully, expired, or invalidated.
- Litigation or licensing agreements could shape its reach, especially if the patent covers critical synthesis steps or formulations.
Key Takeaways
- RE43916's scope centers on methods and compositions related to a specific pharmaceutical agent.
- Its claims are narrowly tailored to particular synthesis techniques or drug formulations.
- The patent landscape involves multiple patents in the same therapeutic space, influencing freedom to operate.
- Enforcement depends on the validity of the claims and potential challenges in patent tribunals.
FAQs
1. What is a reissue patent?
A reissue patent corrects errors in an original patent and can modify claims to clarify scope or extend protection.
2. How broad are the claims typically in RE43916?
Claims tend to be narrow, focusing on specific synthesis methods, formulations, or treatment methods, limiting the scope but increasing enforceability.
3. How does RE43916 compare to related patents in the same space?
It likely complements other patents covering active compounds, delivery systems, or therapeutic uses, forming part of a layered patent family.
4. Can the patent be challenged?
Yes, through legal proceedings such as inter partes review or patent invalidation, especially if prior art demonstrates lack of novelty or obviousness.
5. What is the potential for licensing or enforcement?
Depends on the validity of the claims, patent holder's strategic interests, and the presence of competing patents.
References
- U.S. Patent and Trademark Office (USPTO). Patent RE43916. Retrieved from [USPTO database].
- MPEP (Manual of Patent Examining Procedure). Section 1504. Reissues and reexamination procedures.
- WIPO. Patent landscape reports for pharmaceutical compounds.
- European Patent Office. Patent family analyses relevant to US Patent RE43916.
- Court records or legal analysis reports related to patent enforcement actions, if available.
(Note: Specific patent documents and legal case references are not provided here but should be consulted for detailed legal status and claims analysis.)
More… ↓
⤷ Start Trial
|
